Skip to main navigation Skip to search Skip to main content

Novobiocin precipitates histones at concentrations normally used to inhibit eukaryotic type II topoisomerase

  • Matt Cotten
  • , Doherty Bresnahan
  • , Sally Thompson
  • , Linda Sealy
  • , Roger Chalkeley

Research output: Contribution to journalArticlepeer-review

Abstract

At concentrations normally used to inhibit eukaryotic type II topoisomerase activity (100-1000 μg/ml) novobiocin binds core histones. Approximately 15 moles of novobiocin bind per mole of histone resulting in histone precipitation from solution in either 0.15 M or 2 M NaCl. The interaction between novobiocin and proteins appears to involve arginine residues: histones H3 and H4 (13.5 and 14 mole percent arginine) are precipitated at lower novobiocin concentrations than histones H2A and H2B (9.5 and 6.5 mole percent arginine). Furthermore, polyarginine but not polyornithine competes for novobiocin in histone precipitation. Moreover, histones with arginine residues modified with 1,2-cyclohexanedione are soluble in 1000 μg/ml novobiocin. Because novobiocin can remove histones from solution as well as inhibit topoisomerase activity, and because both of these events can alter DNA topology, novobiocin should be used with caution in experiments designed to implicate topoisomerase activity in chromatin dynamics.

Original languageEnglish (US)
Pages (from-to)3671-3686
Number of pages16
JournalNucleic acids research
Volume14
Issue number9
DOIs
StatePublished - May 12 1986
Externally publishedYes

ASJC Scopus subject areas

  • Genetics

Fingerprint

Dive into the research topics of 'Novobiocin precipitates histones at concentrations normally used to inhibit eukaryotic type II topoisomerase'. Together they form a unique fingerprint.

Cite this